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This guideline presents current management recommen-
dations which may be modified and altered in justifiable cases, 
after careful analysis of a given clinical case, which in the future 
might constitute grounds for modification and updating. 
OBJECTIVES
The objective of this guideline is to present up-to-date 
knowledge about the application of hysteroscopy in gyne-
cology, based on the experience of the authors and reliable 
sources from the literature.
INTRODUCTION
Hysteroscopy is a minimally invasive procedure which 
is performed to diagnose and treat diseases of the uterine 
cavity and the cervical canal. The two types of the pro-
cedure include diagnostic and operative hysteroscopy. 
Diagnostic hysteroscopy allows for a direct visualization 
of the cervical canal, uterine cavity and tubal ostia and, 
if necessary, a targeted biopsy. Operative hysteroscopy facili-
tates intrauterine and/or intracervical lesion excision using 
mechanical or electrosurgical resection methods as well 
as laser techniques. Due to technological advances and 
miniaturization of the hysteroscopic tools, the number 
of diagnostic hysteroscopies with simultaneous excision 
of the lesions (the so-called ‘see-and-treat’ hysteroscopy) 
is steadily increasing [1, 2]. 
Hysteroscopy is a safe procedure and is well-tolerated 
by the patients [3].
INDICATIONS FOR HYSTEROSCOPY 
Due to the wide range of possible applications of uter-
ine cavity and cervical canal imaging, the list of indications 
for hysteroscopy continues to expand. Also, hysteroscopy 
allows to collect tissue samples, when necessary. 
The indications for hysteroscopy include [3–7]: 
 Ū Abnormal uterine bleeding in reproductive age women;
 Ū Post-menopausal bleeding;
 Ū Suspicion of endometrial hyperplasia and other endome-
trial pathologies (endometrial polyps, diagnostic process 
for endometrial hyperplasia and endometrial cancer);
 Ū Corroboration of histopathology results;
 Ū Suspicion of submucosal or intramural fibroids;
 Ū Suspicion of congenital uterine anomaly;
 Ū Suspicion of intrauterine adhesions;
 Ū Corroboration of ultrasound diagnosis of uterine ab-
normalities;
 Ū Repositioning and/or removal of an intrauterine device 
or other foreign bodies from the uterine cavity; 
 Ū Suspicion of retained products of conception; 
 Ū Suspicion of lesions within the cervical canal;
 Ū Part of the diagnostic process for infertility and/or recur-
rent miscarriage; 
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 Ū Endometrial ablation/resection; 
 Ū Vaginoscopy (e.g. removal of a foreign body from the 
vagina in young girls – virgo). 
Indications for hysteroscopy may also include clinical 
situations in which uterine cavity, cervical canal and tubal 
ostia imaging is vital for the diagnostic and therapeutic 
management of the affected patients, e.g. treatment of 
symptomatic niche in the cesarean section scar, injection 
of methotrexate or other pharmacological agents into the 
gestational sac located in the cesarean section scar, diagnos-
tic and/or operative hysteroscopy, with or without biopsy, 
before operative procedures in gynecology [8, 9]. 
In case of suspicion of intrauterine lesions, hysteros-
copy is used during the diagnostic process for infertil-
ity, recurrent miscarriage or before assisted reproductive 
techniques (ART). At present, hysteroscopy is not routinely 
recommended in the diagnosis of infertility or before IVF 
procedures if ultrasonographic appearance of the uterus 
is normal [10–13]. 
CONTRAINDICATIONS TO HYSTEROSCOPY 
Absolute contraindications to hysteroscopy include [3, 14]:
 Ū suspected or diagnosed normal viable intrauterine 
pregnancy;
 Ū active infection of the genital organs, including herpes 
simplex of the genital area; 
 Ū cervical cancer.
Relative contraindications to hysteroscopy include:
 Ū excessive uterine bleeding; 
 Ū severe systemic disease. 
Bleeding from the genital tract is not an absolute con-
traindication to hysteroscopy but obstructed visualization of 
the intrauterine structures may be expected. In such cases, 
it is necessary to select adequate instruments (flow hystero-
scope with proper diameter and isoosmotic medium) [15].
INSTRUMENTS
Types of hysteroscopes
Both, for the operative and diagnostic hysteroscopy, the 
type of the hysteroscope should be adjusted to the type of 
the procedure and operator’s experience, as well as modified 
to the intraoperative conditions [4, 16, 17]. It is advisable to 
use a hysteroscope with the smallest possible diameter of 
the sheath, individually tailored to the needs of the patient, 
and allowing for optimal visualization and least traumatic 
procedure [3, 4, 18]. 
Media types 
Visualization of the intrauterine structures requires dis-
tension of the uterine cavity using medium agents. The 
choice of the distending medium for hysteroscopy is at 
the discretion of the operator. At present, the 0.9% sodium 
chloride (NaCl) is the liquid medium of choice for diagnostic 
hysteroscopy [3, 18, 19]. Other than in exceptional situations, 
a gaseous medium — carbon dioxide (CO2) — is not advis-
able in order to avoid the presence of gas embolism [3]. Also, 
the use of 0.9% NaCl is associated with lower frequency of 
vasovagal syncope as compared to CO2 [4]. A liquid me-
dium, as opposed to gaseous one, allows to wash out the 
mucus and the blood from the uterine cavity, thus improving 
visualization and shortening the duration of the procedure 
[20, 21]. For operative hysteroscopy, only liquid media are 
used. Their advantage consists in washing out the tissue 
fragments and blood which occur during intrauterine lesion 
excision, thus obtaining adequate view of the uterine cavity 
during the procedure [18–20]. 
Liquid media are subcategorized into: 
 Ū non-electrolyte dissension media (5% mannitol, 3% 
sorbitol, and 1.5% glycine) and
 Ū isotonic electrolyte-containing media (0.9% sodium 
chloride, Ringer’s solution). 
As for electric conductivity, non-electrolyte dissension 
media are nonconductive, so they are used during proce-
dures with monopolar electrodes [3, 18]. On the downside, 
they are hypotonic. In the event of excessive absorption 
into the circulatory system, they may lead to fluid over-
load, hyponatremia, and lowered plasma osmolarity, which 
might result in cerebral edema or even death [3, 18, 22]. 
Electrolyte-containing media are electrically conductive and 
cannot be used for procedures with monopolar electrodes 
[3, 18–20]. They are, however, the medium of choice for 
operative hysteroscopy with bipolar electrodes [3, 18]. Their 
isotonicity is their primary advantage, as they reduce the 
risk for hyponatremia and lowered plasma osmolarity.  
BEST PRACTICE IN HYSTEROSCOPY
Eligibility criteria
Patients are deemed eligible for the procedure on the 
basis of the pelvic exam and medical history. Additionally, 
an ultrasonographic examination should be performed, 
using transvaginal probe, if possible. In justified cases, addi-
tional imaging methods (i.e. sonohysterography and nuclear 
magnetic resonance) may also be applied during patient 
eligibility check. The abovementioned methods, unlike hys-
teroscopy, allow for the assessment of the myometrium and 
the external uterine contour. Additional imaging methods, 
especially transabdominal or transrectal ultrasound, and 
sometimes laparoscopy, can be used intraoperatively and 
may increase both, safety and effectiveness of some ad-
vanced hysteroscopic procedures [23–25]. 
Informed consent 
Written informed consent must always be obtained 
before every hysteroscopic procedure. It is necessary to 
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discuss the following with the patient: hysteroscopy type, 
benefits and risk related to the procedure, and alternative 
methods of management. 
Timing of the procedure
For menstruating women, the first phase of the cycle, 
immediately after the bleeding ceases, is the optimal time 
to carry out the procedure, as the endometrium in the early 
proliferative phase is thin and allows for a better visualiza-
tion of the intrauterine structures and possible pathologies 
[3]. In the secretory phase, thickened endometrium may 
impede imaging and visualization, thus increasing the risk 
for misdiagnosis (underdiagnosis of small lesions and over-
diagnosis of endometrial polyps). 
In post-menopausal women, hysteroscopy may be per-
formed at any given time.
Cervical preparation 
Difficulty in inserting the hysteroscope through the 
cervical canal into the uterine cavity is among the main 
causes for unsuccessful hysteroscopy and is responsible 
for approximately 50% of the related complications [4, 26]. 
Therefore, in selected cases of operative hysteroscopy, phar-
macological preparation of the cervix using misoprostol 
(vaginally, 200–400 µg) is allowed [3, 4, 27–30]. Randomized 
studies found no proof of increased number of successful 
procedures or lowered risk for complications or pain reduc-
tion for diagnostic hysteroscopy [27–29, 31]. Thus, routine 
use of misoprostol for cervical preparation before diagnostic 
hysteroscopy is not recommended [4]. 
Notably, the use of misoprostol for cervical preparation 
is an off-label approach.
In cases of cervical stenosis, osmotic distending media, 
intraoperative ultrasound, vaginoscopic approach, manual 
dilation and hysteroscopic dissection of the stenotic cervical 
canal may be also applied [26, 32]. 
Endometrial preparation 
Pre-operative administration of the endometrial thin-
ning agents may be considered in women undergoing elec-
tive operative hysteroscopy (e.g. uterine septum resection, 
submucosal fibroid resection, endometrial ablation) to en-
sure a better view during the procedure [33]. Such manage-
ment is not recommended for diagnostic hysteroscopy as it 
might affect the histopathology results. 
Vaginal preparation 
After excluding the contraindications to hysteroscopy 
(like active inflammation of the genital organs), vaginal 
discharge ought to be examined before the procedure. 
If no signs of inflammation are present, hysteroscopy may 
be conducted. Culture of the cervix is not routinely required. 
It is advisable to visualize the vaginal portion of the cervix 
using the speculum and wash the vagina and the vaginal 
portion with an antiseptic solution suitable for mucous 
membranes. Vaginoscopic approach (i.e. the so-called ‘no 
touch’ technique) is also allowed [4, 34, 35]. It consists in 
insertion of the hysteroscope into the vagina, through the 
cervical canal and into the uterine cavity without the use 
of a speculum or cervical instrumentation. Vaginoscopic 
approach is recommended in situations when it is difficult 
or impossible to insert a speculum. The procedure may 
be conducted without the need to disinfect the vagina if 
vaginal discharge is normal. 
Settings
Advances in technology and increasing miniaturization 
of the hysteroscopes allow to conduct diagnostic and simple 
operative hysteroscopies in outpatient settings [4, 36, 37]. 
The decision between outpatient and hospital setting 
should be made with caution. 
Hospital settings should be recommended to patients 
with: [3, 38]:
 Ū intrauterine lesions which require advanced operative 
procedures;
 Ū cervical stenosis or atresia;
 Ū concomitant diseases which elevate the risk for com-
plications;
 Ū limited uterine maneuverability;
 Ū no tolerance of local anesthesia.
In the remaining cases, ambulatory settings may be 
recommended to patients. 
Elimination of perioperative pain
Hysteroscopy-related pain remains to be one of the 
main limitations for a successful procedure in ambulatory 
settings, so it is vital to be familiar with techniques of pain 
reduction [38, 39]. Friendly atmosphere and engaging the 
patient in a conversation play a significant role in reduc-
ing pain and anxiety associated with the procedure [40]. 
Depending on the emotional condition of the patient and 
her attitude, anesthesia in not necessary during a diagnostic 
hysteroscopy in most women [41, 42]. The benefits of avoid-
ing anesthesia include shortened time of the procedure 
and no adverse effects, especially no pain associated with 
paracervical block [41]. 
Also, small-diameter sheath hysteroscopes are key el-
ements in pain reduction. Randomized studies revealed 
that the use of hysteroscopes with sheath diameter less 
than 4 mm correlates with significantly less pain as com-
pared to the use of higher diameter hysteroscopes with 
simultaneous paracervical block [43]. 
Opioids reduce pain during and after the procedure, but 
caution is advised due to possible adverse effects [4, 44]. 
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Non-steroidal anti-inflammatory agents (NSAIDs) do not 
relieve the pain during hysteroscopy but significantly reduce 
it after the procedure [4, 45]. Local anesthetics, e.g. lidocaine 
spray on the vaginal portion of the cervix, is not an effec-
tive means of pain relief during hysteroscopy [46]. Likewise, 
lidocaine and mepivacaine administration into the cervical 
canal proved ineffective [46]. 
Paracervical block using lidocaine or mepivacaine reduces 
pain associated with cervical dilation and endometrial biopsy, 
and lowers the risk for severe pain during hysteroscopy [47], 
so it should be considered in cases when cervical dilation is nec-
essary or when intrauterine lesions are to be removed [4, 47]. 
Sedation, regional or general anesthesia should not be 
used in ambulatory settings as they require strict monitoring 
of the vital signs and are connected with possible compli-
cations [48]. They should only be administered in setting 
where adequate anesthesiologic standards are maintained. 
HYSTEROSCOPIC BIOPSY 
Hysteroscopic endometrial biopsy should replace di-
agnostic curettage of the uterine cavity [49]. Sensitivity of 
the hysteroscopic endometrial biopsy is significantly higher, 
especially in case of focal lesions. Diagnostic curettage of the 
uterine cavity, if conducted as a sole diagnostic procedure, is 
not sufficient for full diagnostics of the endometrium in case 
of focal lesions [50, 51]. Therefore, hysteroscopy and targeted 
biopsy should be considered in women with indications for 
histopathological examination of the endometrium (e.g. in 
the diagnosis of endometrial cancer) [51, 52]. It makes it pos-
sible to collect focal lesions, which might otherwise be omit-
ted during blind biopsy or curettage, for evaluation [51, 52]. 
In case of extensive suspicious changes in the uterine cavity, 
subsequent curettage is allowed.
It is not always possible to obtain enough endometrial 
tissue for histopathologic evaluation, especially in post-
menopausal women with endometrial atrophy [53–55]. 
In a meta-analysis of studies on endometrial biopsy, non-di-
agnostic histopathology results were found in as many as 
54% of the women with post-menopausal bleeding [54]. 
According to reliable reports in the literature, results of imag-
ing studies are sufficient to plan further management in case of 
patients with non-diagnostic histopathology results [53–55]. 
If hysteroscopy confirmed atrophic endometrium and his-
topathology results are non-diagnostic, repeat biopsy is 
not necessary, unless new indications are present [53–55]. 
Risk for tumor cell dissemination in the 
peritoneal cavity
Hysteroscopy is associated with a certain risk for tu-
mor cell dissemination into the peritoneal cavity due to 
the passage of the medium through the fallopian tubes. 
The available data are not conclusive with regard to a possi-
ble increase in the incidence of positive peritoneal cytology 
after the use of hysteroscopy in the diagnosis of endome-
trial cancer. So far, various meta-analyses have found a link 
between the use of liquid media and higher incidence of 
positive peritoneal cytology, but no relationship between 
potential tumor cell dissemination and disease progression 
was detected [56–61]. 
In order to reduce the risk for cell dissemination in cases 
of suspected endometrial cancer, it is advisable to use the 
lowest possible pressure of the distending medium, pref-
erably not exceeding 50 mmHg. In a study using saline 
solution and intrauterine pressure of 25–50 mmHg, the 
authors found that hysteroscopy did not increase the risk 
for microscopic intraperitoneal tumor cell dissemination 
as compared to curettage [62]. More prospective studies 
in that area are necessary. 
COMPLICATIONS OF HYSTEROSCOPY AND 
THEIR PREVENTION 
Early complications:
 Ū uterine perforation;
 Ū heavy bleeding;
 Ū absorption of the distending medium;
 Ū gas embolism;
 Ū fluid overload. 
Late complications:
 Ū iatrogenic adhesions after hysteroscopy;
 Ū pelvic inflammatory disease. 
Uterine perforation
The incidence of uterine perforation during diagnostic 
and operative hysteroscopy has been estimated at 0.13% 
and 0.5–3%, respectively [62, 63]. Perforation may occur 
either during the attempt to enter the uterine cavity or 
intraoperatively, during lesion excision. Risk factors for per-
foration during hysteroscope insertion include [4, 63]:
 Ū cervical stenosis and the need for cervical dilation 
(as a result of atrophy, previous surgery, or no previous 
vaginal delivery);
 Ū torsion of the cervical canal and uterine cavity (fre-
quently occurs in case of fibroids and pelvic adhesions).
The highest risk for uterine perforation is associated 
with the excision of massive intrauterine adhesions [63]. 
Should perforation occur, it is possible to either monitor the 
patient or consider performing laparoscopy or laparotomy 
to stop the bleeding and assess for possible intestine or 
bladder trauma [3]. Assessment of the bowel and the blad-
der is necessary in the event of uterine perforation using 
an electrosurgical tool or laser due to the risk for thermal 
injury [64]. Suturing of the uterine perforation is advised in 
reproductive age women to prevent a possible uterine scar 
rupture during subsequent pregnancy [65]. It is important 
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to bear in mind that if the perforation is localized within the 
cervix or the lateral uterine wall, it may cause bleeding into 
the retroperitoneal space [3].
If fundal perforation occurs while using a thin hys-
teroscope, a thin Hegar device, or an uterine probe in 
a post-menopausal woman without signs of bleeding into 
the abdominal cavity, it is possible to simply monitor the 
patient. Detailed imaging to exclude bleeding into the ab-
dominal cavity and a 24-hour monitoring at a postoperative 
care unit are necessary. Should patient clinical and laboratory 
(complete blood count, C-reactive protein) parameters re-
main stable after 24 hours, the perforation may be diagnosed 
as non-symptomatic and not requiring surgical intervention. 
In cases when hysteroscopic entry is difficult, it is advis-
able to establish the path of the cervical canal and its rela-
tion to the uterine axis before ‘blind’ cervical dilation [3, 26]. 
For that purpose, a small-diameter flexible or rigid hystero-
scope may be used, which allows for visual control during 
dilation of the cervical canal with the tip of the hysteroscope 
or microtools inserted through the operative channel [26]. 
Uterine probe, bimanual examination, transvaginal, tran-
srectal or transabdominal ultrasound are also useful while 
attempting to establish the path of the cervical canal and its 
relation to the uterine cavity. Difficulty with hysteroscopic 
entry into the uterine cavity may be reduced by cervical 
preparation with misoprostol [29]. 
Hemorrhage 
Clinically significant bleeding during diagnostic hyster-
oscopy is rare and is usually associated with uterine perfora-
tion. The incidence of clinically significant bleeding related 
to operative hysteroscopy has been estimated at 0.61% [63]. 
Apart from uterine perforation, other causes for bleeding 
include cervical trauma, bleeding at the operation site or 
bleeding diathesis. 
In the event of intraoperative bleeding, coagulation 
using mono- and bipolar electrodes may be applied (the 
choice of the electrodes depends on the medium used 
during the procedure). 
Postoperative bleeding from the uterine cavity may be 
stopped by using uterotonics, antifibrinolytics, or balloon 
tamponade (e.g. using a Foley’s catheter).
If none of the above methods proved sufficient, it may 
be necessary to perform uterine artery embolization or 
hysterectomy. The patient should be made aware of that 
risk and information about a possible hysterectomy should 
be included in the informed consent for all hysteroscopic 
procedures [3, 63].
Embolism
Air embolism may occur during hysteroscopy using 
either gaseous medium — CO2 or liquid medium, as air 
bubbles are present in the liquid medium as well [18, 66]. 
The symptoms include dyspnea, chest pain, tachycardia, 
anxiety, sudden hypotension and hypoxemia [18]. Vascular 
access and a pressure gradient are necessary for CO2 or air 
to get into the cardiovascular system, and then to the right 
ventricle and to the pulmonary arteries [3]. Therefore, to 
avoid this complication, it is vital to keep the rate of the 
CO2 flow below 100 mL/min., and the uterine cavity pressure 
below 100 mmHg [3]. Importantly, laparoscopic insufflators 
should not be used for hysteroscopic procedures as they 
have very high CO2 flow rate [3]. Carbon dioxide should 
not be used during operative hysteroscopy due to the risk 
for CO2 passage into the open vessels [18]. To avoid air 
passage into the uterine cavity during hysteroscopy with 
liquid medium, tubing and hysteroscopy channel ought to 
be flushed until all air bubbles are removed. Caution is also 
advised when bags containing liquid media are changed to 
avoid air entering tubing [3].
FLUID OVERLOAD 
Operative hysteroscopy intravascular absorption syn-
drome (OHIA) occurs when a significant amount of the liquid 
medium is absorbed into the circulation [63, 67]. At present, 
the incidence of OHIA has been estimated at < 1% [18, 63, 
68, 69]. The absorption occurs by the opened uterine veins as 
a result of pressure gradient (venous pressure: 10–15 mmHg, 
distending media pressure in the intrauterine cavity: 40–
60 mmHg) [63]. Absorption of the distention media may also 
occur by peritoneal surface due to the retrograde passage 
of the fluid through the Fallopian tubes [18]. 
Risk factors for fluid overload include high (excessing 
the mean blood pressure) pressure in the uterine cavity, 
prolonged duration of the procedure, and contact between 
the medium and the opened myometrial venous sinuses 
(mainly during electrosurgical fibroid resection or the resec-
tion of the endometrium) [70–72]. 
Massive absorption of a hypotonic medium (glycine, 
mannitol, sorbitol) leads to hyponatremia, which is mani-
fested with headache, nausea, vomiting and fatigue. In case 
when sodium levels drop below < 120 mmol/L, lowered 
plasma osmolarity will lead to cerebral edema, including 
the risk for brain herniation [3, 28, 73].
Massive absorption of an isotonic medium (0.9% sodium 
chloride, Ringer’s solution) will not cause electrolyte imbal-
ance but may lead to hypervolemia with pulmonary edema 
and heart failure [3, 18].
In accordance with the international consensus, a fluid 
deficit (difference between the volume of fluid infused into 
the uterus and the volume of fluid evacuated from the 
uterus) should not exceed 1000 mL for hypotonic (glycine, 
mannitol, sorbitol) and 2500 mL for isotonic solutions. These 
thresholds apply to healthy reproductive age women [18]. 
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In case of elderly women with renal and cardiovascular 
problems, the upper fluid deficit levels should be 750 mL 
and 1500 mL, respectively [19]. Therefore, careful monitoring 
of the fluid deficit during hysteroscopy is necessary. The pro-
cedure should be stopped when the fluid deficit is reaching 
the abovementioned limits or when the clinical symptoms 
of fluid overload occur. In order to lower the risk for hypona-
tremia and the related complications, iso-osmotic media 
such as 0.9% sodium chloride or Ringer’s solution should 
be the preferred choice for operative hysteroscopy [18]. 
The information about fluid deficit should be included 
in the operation report. 
Iatrogenic adhesions after hysteroscopy 
Hysteroscopic resection of the intrauterine lesions is 
associated with significantly lower risk for de novo adhesion 
formation as compared to curettage [74]. Therefore, uterine 
curettage in order to obtain endometrial samples in wom-
en undergoing diagnosis for infertility should be avoided. 
The incidence of adhesion formation after operative hyster-
oscopy depends on the type of the procedure. Polypectomy 
is associated with the lowest and multiple submucosal fi-
broid resection with the highest risk for adhesion formation, 
respectively [74]. The following procedures may decrease 
the risk for intrauterine adhesion formation after hysteros-
copy: avoidance of electrosurgical tools, early second-look 
hysteroscopy, estrogen therapy, intrauterine systems (IUD, 
balloon), stem cells, hyaluronic acid gels or carboxymethyl 
cellulose gels [74–76]. At present, we lack reliable data advo-
cating routine use of any of the abovementioned methods 
of preventing adhesions after hysteroscopy [75].
Pelvic inflammatory disease 
The incidence of inflammatory diseases after hystero-
scopic procedures has been estimated at < 1%, so routine 
antibiotic prophylaxis is not required [77–79]. Guidelines on 
patient eligibility and preparation for the procedure, which 
constitute preventive measures for post-hysteroscopic in-
flammation, have been presented earlier in the text. 
SUMMARY 
The benefits of diagnostic hysteroscopy include direct 
visualization of the intrauterine structures and, when neces-
sary, performing a minimally invasive targeted biopsy for 
histopathology evaluation.
Operative hysteroscopy allows for a minimally invasive 
excision of intrauterine lesions. 
Hysteroscopy is well-tolerated and safe for the patients. 
Hysteroscopy is the basis of the modern diagnostic pro-
cess and the treatment of uterine diseases, and every effort 
should be made to increase its availability in Poland.
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